MiR-196a is upregulated in gastric cancer and promotes cell proliferation by downregulating p27 kip1

Molecular Cancer Therapeutics

Volumn 11, Issue 4, 2012, Pages 842-852

  Sun, Ming ^a   Liu, Xiang Hua ^a   Li, Jin Hai ^a   Yang, Jin Song ^a   Zhang, Er Bao ^a   Yin, Dan Dan ^a   Liu, Zhi Li ^b   Zhou, Jing ^b   Ding, Ying ^a   Li, Su Qin ^a   Wang, Zhao Xia ^b   Cao, Xiu Feng ^a   De, Wei ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B;

3' UNTRANSLATED REGION; APOPTOSIS; ARTICLE; BINDING SITE; CANCER TISSUE; CARCINOGENESIS; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; GENE FUNCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MICRORNA 196A GENE; ONCOGENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; STOMACH CANCER; TUMOR GROWTH; UPREGULATION; WESTERN BLOTTING;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; STOMACH NEOPLASMS; TRANSFECTION; UP-REGULATION;

EID: 84862742561     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-1015     Document Type: Article

References (37)

1. Herszenyi L, Tulassay Z. Epidemiology of gastrointestinal and liver tumors. Eur Rev Med Pharmacol Sci 2010;14:249-58.
2. Catalano V, Labianca R, Beretta GD, Gatta G, de Braud F, Van Cutsem E. Gastric cancer. Crit Rev Oncol Hematol 2009;71:127-64.
3. Vogiatzi P, Vindigni C, Roviello F, Renieri A, Giordano A. Deciphering the underlying genetic and epigenetic events leading to gastric carcinogenesis. J Cell Physiol 2007;211:287-95. (Pubitemid 46580082)
4. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol 2006;12:354-62. (Pubitemid 43329250)
5. Pinheiro H, Bordeira-Carrico R, Seixas S, Carvalho J, Senz J, Oliveira P, et al. Allele-specific CDH1 downregulation and hereditary diffuse gastric cancer. Hum Mol Genet 2010;19:943-52.
6. Selbach M, Schwanhausser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N. Widespread changes in protein synthesis induced by microRNAs. Nature 2008;455:58-63.
7. Wu WK, Lee CW, Cho CH, Fan D, Wu K, Yu J, et al. MicroRNA dysregulation in gastric cancer: a new player enters the game. Oncogene 2010;29:5761-71.
8. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97.
9. Chaudhuri K, Chatterjee R. MicroRNA detection and target prediction: integration of computational and experimental approaches. DNA Cell Biol 2007;26:321-37. (Pubitemid 46799181)
10. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature 2005;435:834-8. (Pubitemid 40839735)
11. Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 2007;39:673-7. (Pubitemid 46676103)
12. Wang D, Qiu C, Zhang H, Wang J, Cui Q, Yin Y. Human microRNA oncogenes and tumor suppressors show significantly different biological patterns: from functions to targets. PLoS One 2010;5:e13067.
13. Kumar MS, Erkeland SJ, Pester RE, Chen CY, Ebert MS, Sharp PA, et al. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci U S A 2008;105:3903-8. (Pubitemid 351723497)
14. Esquela-Kerscher A, Trang P, Wiggins JF, Patrawala L, Cheng A, Ford L, et al. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle 2008;7:759-64. (Pubitemid 351520040)
15. Mori. Clinicopathological and prognostic significance of PDCD4 and microRNA-21 in human gastric cancer. Int J Oncol 2010;36:1089-95.
16. Shinozaki A, Sakatani T, Ushiku T, Hino R, Isogai M, Ishikawa S, et al. Downregulation of microRNA-200 in EBV-associated gastric carcinoma. Cancer Res 2010;70:4719-27.
17. Zhang X, Zhu W, Zhang J, Huo S, Zhou L, Gu Z, et al. MicroRNA-650 targets ING4 to promote gastric cancer tumorigenicity. Biochem Biophys Res Commun 2010;395:275-80.
18. Xu T, Zhu Y, Xiong Y, Ge Y-Y, Yun J-P, Zhuang S-M. MicroRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells. Hepatology 2009;50:113-21.
19. Zhang SZ. Knockdown of c-Met by adenovirus-delivered small interfering RNA inhibits hepatocellular carcinoma growth in vitro and in vivo. Mol Cancer Ther 2005;4:1577-84.
20. Yang F, Sarangarajan R, Le Poole IC, Medrano EE, Boissy RE. The cytotoxicity and apoptosis induced by 4-tertiary butylphenol in human melanocytes are independent of tyrosinase activity. J Invest Dermatol 2000;114:157-64. (Pubitemid 30195989)
21. Wang R, Wang ZX, Yang JS, Pan X, De W, Chen LB. MicroRNA-451 functions as a tumor suppressor in human non-small cell lung cancer by targeting ras-related protein 14 (RAB14). Oncogene 2011;30:2644-58.
22. Guan Y, Mizoguchi M, Yoshimoto K, Hata N, Shono T, Suzuki SO, et al. MiRNA-196 is upregulated in glioblastoma but not in anaplastic astrocytoma and has prognostic significance. Clin Cancer Res 2010;16:4289-97.
23. Schimanski CC. High miR-196a levels promote the oncogenic phenotype of colorectal cancer cells. World J Gastroenterol 2009;15:2089.
24. Luthra R, Singh RR, Luthra MG, Li YX, Hannah C, Romans AM, et al. MicroRNA-196a targets annexin A1: a microRNA-mediated mechanism of annexin A1 downregulation in cancers. Oncogene 2008;27:6667-78.
25. Braig S, Mueller DW, Rothhammer T, Bosserhoff A-K. MicroRNA miR-196a is a central regulator of HOX-B7 and BMP4 expression in malignant melanoma. Cell Mol Life Sci 2010;67:3535-48.
26. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995;9:1149-63.
27. Kawamata N, Morosetti R, Miller CW, Park D, Spirin KS, Nakamaki T, et al. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res 1995;55:2266-9.
28. Sheaff RJ, Groudine M, Gordon M, Roberts JM, Clurman BE. Cyclin ECDK2 is a regulator of p27Kip1. Genes Dev 1997;11:1464-78.
29. Hong YB, Kang HJ, Kim HJ, Rosen EM, Dakshanamurthy S, Rondanin R, et al. Inhibition of cell proliferation by a resveratrol analog in human pancreatic and breast cancer cells. Exp Mol Med 2009;41:151.
30. Russo AA, Jeffrey PD, Patten AK, Massague J, Pavletich NP. Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. Nature 1996;382:325-31. (Pubitemid 26260452)
31. Wang X, Gorospe M, Huang Y, Holbrook NJ. p27Kip1 overexpression causes apoptotic death of mammalian cells. Oncogene 1997;15:2991-7. (Pubitemid 28008992)
32. Zhang Q, Tian L, Mansouri A, Korapati A, Johnson T, Claret F. Inducible expression of a degradation-resistant form of p27Kip1 causes growth arrest and apoptosis in breast cancer cells. FEBS Lett 2005;579:3932-40. (Pubitemid 40961891)
33. Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, et al. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 1997;3:227-30. (Pubitemid 27064710)
34. Mori M, Mimori K, Shiraishi T, Tanaka S, Ueo H, Sugimachi K, et al. p27 expression and gastric carcinoma. Nat Med 1997;3:593.
35. Cordon-Cardo C, Koff A, Drobnjak M, Capodieci P, Osman I, Millard SS, et al. Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J Natl Cancer Inst 1998;90:1284-91. (Pubitemid 28433473)
36. Esposito V, Baldi A, De Luca A, Groger AM, Loda M, Giordano GG, et al. Prognostic role of the cyclin-dependent kinase inhibitor p27 in nonsmall cell lung cancer. Cancer Res 1997;57:3381-5. (Pubitemid 27355479)
37. Peter ME. Targeting of mRNAs by multiple miRNAs: the next step. Oncogene 2010;29:2161-4.